Table 2. Epidemiological assumptions, vaccine effectiveness and vaccination coverage underlying the model.
| Parameter | Baseline | Range | Sources |
|---|---|---|---|
| Total infants birth (2013) | 346,400 | [16] | |
| Epidemiological assumptions (%) | |||
| Prevalence of HBsAg among mothers | 12 | 4–15 | [6][8][9][18][19] |
| Prevalence of HBeAg among HBsAg positive mothers | 30 | 20–40 | [4] |
| Vaccine effectiveness (risk of perinatal infection, %) | |||
| Neonates with HBIG born to | |||
| HBeAg positive mothers | 12.5 | 6.4–29 | [24][25][26][27][28][30] |
| HBeAg negative mothers | 1 | 0–3 | [25][27][30][31] |
| Neonates without HBIG born to | |||
| HBeAg positive mothers | 33.8 | 21–43 | [26][27][28] |
| HBeAg negative mothers | 6.6 | 0–13.2 | [25][27][29] |
| Neonates without TBD born to | |||
| HBeAg positive mothers | 87.5 | 62.6–96.7 | [29] |
| HBeAg negative mothers | 13.2 | 2.6–46.2 | [29] |
| Coverage of vaccination (%) | |||
| TBD of current vaccination | 0 | 0–20 | Assumed |
| TBD of universal vaccination | 75 | 50–90 | Assumed |
| TBD of selective vaccination | 75 | 50–90 | Assumed |
| Screening test (%) | |||
| Sensitivity | 99 | 94.5–100 | [22] |
| Specificity | 97.8 | 94.3–99.4 | [22] |
HBsAg, Hepatitis B surface Antigen; HBeAg, Hepatitis B envelope Antigen; HBIG, Hepatitis B Immune Globulin; TBD, Timely Birth Dose